Skip to content

Respiratory Tele Monitoring COVID 19 (TMR COVID-19)

Interest of Respiratory Tele Monitoring in COVID-19 Pneumonia

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04821973
Enrollment
80
Registered
2021-03-30
Start date
2020-09-22
Completion date
2021-05-26
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

The determinants of the evolution to a severe form for COVID-19 pneumonia remain unclear. COVID-19 pneumonia is characterized by a hypoxemia with a possible rapid worsening and related resuscitation requirement. The monitoring of patients in hospital wards (excluding intensive care unit) is therefore both necessary and complicated given the contagious risks for health workers. The COVID 19 Respiratory Tele Monitoring (RTM COVID 19) research project is based on a comparison between usual nurse respiratory monitoring (4 to 6 time per day) of respiratory parameters (capillary oxygen saturation, respiratory rate, hearth rate) and a continuous monitoring of these respiratory parameters with continuous monitoring by a portable, wireless and stand-alone device. The main objective of this work is a more sensitive and earlier detection of respiratory degradation events in patients with COVID-19 pneumonia (capillary desaturation, increased respiratory rate) requiring the introduction of oxygen therapy, its increase or a resuscitation requirement with possible intensive care admission. A prospective, randomized, multicentre, comparative exposure study will be conducted with planned inclusion of 80 patients. This investigation will focus on patients with COVID-19 pneumonia hospitalized in dedicated medical wards of two University Hospitals in France. A randomization will be stratified by Hospital and adapted so that each Hospital provides the same number of subjects in each arms: * Control Respiratory Monitoring Group (40 patients) * Experimental Respiratory Monitoring Group (40 patients) The main criterion is respiratory degradation event, during a 4 days period after ward admission, which motivates a change in the therapeutic strategy defined by the presence of at least one of these elements: * Capillary saturation \< 94% (regardless of oxygen intake) for at least 2 minutes. * And/or an increase in respiratory rate \> 20/minute for at least 2 minutes. The modification of the therapeutic strategy is defined by: * Introduction of oxygen therapy for included patients without oxygen therapy or supplementation of oxygen therapy \> 2 litres/minutes for included patients with oxygen therapy * And/or introduction of a high oxygen concentration mask * And/or Request an On-Site Opinion from a member of the resuscitation team. * And/or Transfer to intensive care or resuscitation unit * And/or Need for immediate resuscitation for life-threatening distress.

Interventions

DEVICERadius PPG Tetherless Pulse Oximetry (Masimo)

continuous monitoring by a portable, wireless and stand-alone device

DEVICEusual monitoring

usual nurse respiratory monitoring

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient with COVID 19 pneumonia assessed by PCR and CT scann. * Patient admited in a dedicated medical ward * Patient with oxygen supply less or equal to 4 liters per minute. * Written informed consent

Exclusion criteria

* Patient with limitation of care. * Patient with immediate risk to ICU transfer within the first 12 hours * Patient with neurological or psychiatric symptoms that interfere with respiratory parameters interpretation. * Patient with acute or chronic respiratory disease such as COPD, cancer. * Pregnancy, age \< 18 of vulnerable profile. * Patient refusal to participate or previously included in a clinical research trial.

Design outcomes

Primary

MeasureTime frameDescription
respiratory degradation event 1during the 4 days periodCapillary saturation \< 94% (regardless of oxygen intake) for at least 2 minutes
respiratory degradation event 2during the 4 days periodan increase in respiratory rate \> 20/minute for at least 2 minutes

Secondary

MeasureTime frameDescription
New Early Warning Score (NEWS) evaluationduring the 4 days periodpost hoc comparison of the respiratory monitoring using the experimental device with the NEWS on the repiratory event occurence
Assessment of caregiver feelingsduring the 4 days periodpost hoc analysis of the team in regard to the monitoring strategy used based on a self-assessment questionnaire
Intensive Care Unit tansferduring the 4 days periodpost hoc analysis of the frequency of ICU transfer

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026